STE Stock Recent News

STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.

Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "U.S. Gynecological Chairs and Tables Market Size, Share & Trends Analysis Report by Product (Gynecological Chairs, Gynecological Tables), Application (Urology Surgery, Pelvic Surgery), End-use, with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The U.S. Gynecological Chairs and Tables Market was valued at USD 194.8 Million in 2024, and is projected to reach USD 283.8 Million by 2030, rising at a CAGR of 6.50%.

Examine Steris' (STE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

Steris plc remains a Strong Buy with a fair value of $281, supported by robust organic growth and margin expansion. The Trump administration's push to reshore pharma manufacturing could be a major tailwind for Steris's AST business. Steris's balanced growth in pricing and volume, along with cost initiatives, positions it for continued operating margin improvement.

STERIS plc (NYSE:STE ) Q4 2025 Results Conference Call May 15, 2025 9:00 AM ET Company Participants Julie Winter - Investor Relations Mike Tokich - Senior Vice President and Chief Financial Officer Dan Carestio - President and Chief Executive Officer Conference Call Participants Dave Turkaly - Citizens Mike Matson - Needham & Company Patrick Wood - Morgan Stanley Mac Etoch - Stephens, Inc Michael Polark - Wolfe Research Jason Bednar - Piper Sandler Brett Fishbin - KeyBanc Operator Good morning, everyone, and welcome to the STERIS plc Fourth Quarter 2025 Conference Call. All participants will be in a listen-only mode.

STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.

Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Steris (STE) came out with quarterly earnings of $2.74 per share, beating the Zacks Consensus Estimate of $2.59 per share. This compares to earnings of $2.41 per share a year ago.

DUBLIN, IRELAND, May 14, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 fourth quarter and full year ended March 31, 2025. Total revenue from continuing operations for the fourth quarter of fiscal 2025 increased 4% to $1.5 billion compared with $1.4 billion in the fourth quarter of fiscal 2024. Constant currency organic revenue growth from continuing operations for the fourth quarter was 6%.

Get a deeper insight into the potential performance of Steris (STE) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.